Observations placeholder
Aranesp
Identifier
018007
Type of Spiritual Experience
Background
A description of the experience
Darbepoetin alfa is a synthetic form of erythropoietin. It stimulates erythropoiesis (increases red blood cell levels) and is used to treat anemia. Darbepoetin is marketed under the trade name Aranesp.
The drug was approved in September 2001 by the Food and Drug Administration for treatment of anemia in patients with chronic renal failure by intravenous or subcutaneous injection. In June 2001, it had been approved by the European Medicines Agency for this indication as well as the treatment of anemia in cancer patients undergoing chemotherapy.
Darbepoetin alfa has black box warnings in the United States for increased risk of death, myocardial infarction, stroke, venous thromboembolism, thrombosis of vascular access, and tumor progression or recurrence.
In addition to those listed in the black box warning, use of darbepoetin alfa also increases the risk of cardiovascular problems, including cardiac arrest, arrhythmia, hypertension and congestive heart failure, and edema.
On Dec, 28, 2016 30,776 people reported to have side effects when taking Aranesp.
Among them, 91 people (0.3%) have Hallucinations
Time on Aranesp when people have Hallucination :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Hallucination | 0.00% | 66.67% | 33.33% | 0.00% | 0.00% | 0.00% | 0.00% |
Gender of people who have Hallucination when taking Aranesp :
| Female | Male | |
| Hallucination | 51.19% | 48.81% |
Age of people who have Hallucination when taking Aranesp :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Hallucination | 0.00% | 0.00% | 0.00% | 0.00% | 35.53% | 2.63% | 5.26% | 56.58% |
On Sep, 26, 2015: 13,165 people reported to have side effects when taking Aranesp. Among them, 615 people (4.67%) have Death.
Time on Aranesp when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 44.34% | 25.47% | 6.60% | 6.60% | 14.15% | 2.83% | 0.00% |
Gender of people who have Death when taking Aranesp :
| Female | Male | |
| Death | 50.25% | 49.75% |
Age of people who have Death when taking Aranesp :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Death | 0.68% | 0.00% | 0.68% | 0.00% | 2.25% | 4.05% | 17.34% | 75.00% |